MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Chronic Lymphocytic Leukemia Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,742 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,742 works in the cohort · of 4,299,418page 12 of 35

Labels cover 5 of 1,742 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,742 of 1,742 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
SAT0151 EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Andrea Rubbert‐Roth, Jeffrey Enejosa, Aileen L. Pangan, Ricardo Machado Xavier, Boulos Haraoui, Maureen Rischmueller +4 more
2020· article· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · metaresearch+metaepi_narrowconsensus · none
10
citations
affunlabeled
Clinical trial risk in leukemia: Biomarkers and trial design
Alice Li, Jasper P. Dhanraj, Gilberto Lopes, Jayson L. Parker
2020· review· en· Hematological Oncology· Medicine
distilled prediction:candidate · metaresearch+metaepi_narrow+research_integrityconsensus · research_integrity
9
citations
afffundno abstractunlabeled
An autologous tumor vaccine for CLL
Fang Zhu, Ismat Khatri, David Spaner, Reginald M. Gorczynski
2018· article· en· Leukemia Research· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · insufficient_payload
9
citations
← previousnext →

How this was built: Screen · Findings · About